Neuren Pharmaceuticals Limited (ASX:NEU)
Australia · Delayed Price · Currency is AUD 18.58
+0.46 (2.54%)
Nov 7, 2025, 4:10 PM AEST
Neuren Pharmaceuticals Company Description
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.
It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins.
In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome.
The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Neuren Pharmaceuticals Limited
| Country | New Zealand |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Jonathan Pilcher |
Contact Details
Address: 117 Camberwell Road Hawthorn East, VIC 3123 Australia | |
| Phone | 61 3 9092 0480 |
| Website | neurenpharma.com |
Stock Details
| Ticker Symbol | NEU |
| Exchange | Australian Securities Exchange |
| Fiscal Year | January - December |
| Reporting Currency | AUD |
| ISIN Number | NZNEUE0001S8 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | Chief Executive Officer, MD and Executive Director |
| Lauren Frazer C.A. | Chief Financial Officer and Company Secretary |
| Dr. Clive Blower BSc (Hons), Ph.D. | Chief Operations Officer |
| Lawrence Glass BA (Biology) | Chief Science Officer |
| Gerry Zhao | Chief Business Officer |
| Dr. Liza A. Squires M.D. | Chief Medical Officer |
| Daryl Dekarske | Chief Regulatory Officer |